Ardent Health to Participate in the 2025 Stephens Annual Investment Conference

BRENTWOOD, Tenn.--(BUSINESS WIRE)-- Ardent Health (NYSE: ARDT), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today announced that the Company will participate in the 2025 Stephens Annual Investment Conference on Tuesday, Nov. 18, 2025, in Nashville, Tennessee.

Members of the management team will participate in a fireside chat on Nov. 18, 2025, at 11 a.m. ET. A live audio webcast of the event will be available in the Investor Relations section of the Ardent Health website at ir.ardenthealth.com. A replay of the event will be accessible on the same page following the session.

In conjunction with the conference, the Ardent Health management team will be available to participate in one-on-one meetings with investors registered to attend the conference. For more information, please contact your Stephens sales representative, or Dave Styblo, Ardent Health senior vice president of investor relations at [email protected].

About Ardent Health

Ardent Health (NYSE: ARDT) is a leading provider of healthcare in growing mid-sized urban communities across the U.S. With a focus on people and investments in innovative services and technologies, Ardent is passionate about making healthcare better and easier to access. Through its subsidiaries, the Company delivers care through a system of 30 acute care hospitals and approximately 280 sites of care with over 1,800 employed and affiliated providers across six states. For more information, please visit ardenthealth.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251110097471/en/

Investor contact:
Dave Styblo, CFA
[email protected]
(615) 296-3016

Media contact:
Rebecca Kirkham
[email protected]
(615) 296-3000

Source: Ardent Health

You May Also Be Interested In

• Marcus & Millichap’s IPA Capital Markets Arranges $75.1 Million Recapitalization for The Monroe Hotel in Miami Beach’s Faena District
• ETCAMAH® (camizestrant) in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancer
• Nexcel Metals Announces Equity Grants